Current Value
$24.071 Year Return
Current Value
$24.071 Year Return
SeekingAlpha
Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
Finnhub
Topline data from oral small molecule aleniglipron Phase 2b ACCESS and ACCESS II studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist Phase 1 initiation anticipated...
Yahoo
We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against other promising small-cap stocks. Robert Teeter of Silvercrest Asset Management recently appeared in an interview to express that he thinks small-cap stocks […]
Yahoo
Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Commenting on the news, Leerink said that the once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by Novo Nordisk (NVO). PRIMARY ENDPOINT MET: Eli Lilly anno
Yahoo
JPMorgan analyst Hardik Parikh says Eli Lilly’s (LLY) Phase 3 data for orforglipron in type 2 diabetes suggest a “highly competitive profile” for the drug. The firm views the data as its base case scenario, whereby Structure Therapeutics (GPCR) shares could be up double-digit percent in this scenario on a “highly favorable read-through” and Viking Therapeutics (VKTX) could move mid-single-digit in either direction. JPMorgan’s focus was primarily on orfoglipron’s tolerability profile with the ext
Yahoo
Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 42.20% | $5.19B | 0.35% |
IBB | 34.49% | $5.41B | 0.45% |
GNOM | 33.61% | $42.14M | 0.5% |
PIN | 32.48% | $229.34M | 0.78% |
INDY | 32.33% | $700.48M | 0.89% |
INDA | 31.64% | $9.10B | 0.62% |
EPI | 30.98% | $3.22B | 0.85% |
FBT | 30.67% | $1.05B | 0.56% |
FLIN | 30.44% | $2.17B | 0.19% |
PBE | 30.25% | $224.25M | 0.58% |
ARKG | 30.17% | $920.94M | 0.75% |
PTH | 29.61% | $99.77M | 0.6% |
XPH | 29.28% | $141.28M | 0.35% |
BBH | 29.18% | $340.78M | 0.35% |
PINK | 29.17% | $133.30M | 0.5% |
EFAA | 28.79% | $151.80M | 0.39% |
AOM | 27.96% | $1.49B | 0.15% |
VIGI | 27.90% | $8.11B | 0.1% |
CPRJ | 27.42% | $47.84M | 0.69% |
IBHF | 27.10% | $808.41M | 0.35% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MNDY | 0.01% | $14.71B | +18.38% | 0.00% |
WFG | 0.01% | $5.82B | -9.67% | 1.75% |
FARO | -0.02% | $807.50M | +121.64% | 0.00% |
CMS | -0.03% | $20.75B | +13.95% | 3.03% |
NNBR | 0.04% | $95.85M | -41.18% | 0.00% |
WTRG | 0.05% | $10.81B | +3.91% | 3.35% |
AWR | -0.07% | $3.01B | +4.56% | 2.37% |
VRCA | 0.08% | $57.34M | -92.57% | 0.00% |
ATNI | -0.10% | $216.84M | -38.10% | 6.81% |
PLG | 0.10% | $148.26M | -14.97% | 0.00% |
CVI | -0.12% | $2.40B | -19.59% | 2.13% |
LINC | -0.12% | $676.72M | +82.30% | 0.00% |
KR | -0.13% | $45.24B | +27.46% | 1.85% |
ICFI | 0.14% | $1.62B | -38.32% | 0.65% |
GWRE | -0.14% | $17.45B | +71.41% | 0.00% |
FROG | 0.15% | $4.90B | +28.63% | 0.00% |
VTMX | -0.16% | $2.57B | -19.94% | 2.62% |
AIFU | 0.17% | $191.32M | +5.63% | 0.00% |
VZ | 0.17% | $181.85B | +9.38% | 6.21% |
MTDR | 0.20% | $5.46B | -27.41% | 2.53% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SAIC | -17.29% | $5.78B | -10.43% | 1.24% |
PAC | -12.17% | $9.89B | +16.72% | 0.00% |
PPC | -10.75% | $11.66B | +55.46% | 0.00% |
BOOM | -9.92% | $135.24M | -50.64% | 0.00% |
VHC | -8.86% | $33.82M | +73.48% | 0.00% |
WM | -8.74% | $93.89B | +11.38% | 1.31% |
AMPY | -8.44% | $108.10M | -56.28% | 0.00% |
USPH | -8.14% | $1.15B | -25.00% | 2.40% |
FE | -7.63% | $24.23B | +7.28% | 4.07% |
CCEC | -7.54% | $1.02B | +3.91% | 2.56% |
TXO | -7.33% | $838.20M | -27.59% | 15.77% |
UNH | -7.15% | $269.12B | -42.60% | 2.83% |
EXC | -7.12% | $43.83B | +17.26% | 3.57% |
INVX | -7.12% | $971.22M | -22.72% | 0.00% |
ED | -6.56% | $37.26B | +10.17% | 3.23% |
AGL | -6.41% | $910.69M | -61.06% | 0.00% |
RNGR | -6.29% | $250.85M | +8.46% | 2.01% |
ZBH | -6.14% | $18.14B | -20.87% | 1.06% |
OMAB | -5.93% | $4.21B | +21.10% | 2.22% |
INSP | -5.78% | $4.30B | -5.73% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
USCI | 0.06% | $230.01M | 1.07% |
XHLF | -0.46% | $1.46B | 0.03% |
TFLO | -0.64% | $7.03B | 0.15% |
USFR | 0.72% | $18.91B | 0.15% |
IBMR | -0.78% | $239.25M | 0.18% |
CORN | -0.98% | $50.30M | 0.2% |
WTMF | -1.12% | $157.22M | 0.65% |
TBLL | -1.27% | $2.31B | 0.08% |
SHV | 1.35% | $20.82B | 0.15% |
BILS | 1.39% | $3.92B | 0.1356% |
UNG | 1.46% | $349.65M | 1.06% |
DBC | -1.54% | $1.16B | 0.87% |
SOYB | 1.57% | $25.14M | 0.22% |
CLIP | -1.59% | $1.51B | 0.07% |
ULST | -1.71% | $638.58M | 0.2% |
XLE | 2.00% | $26.90B | 0.09% |
CARY | 2.07% | $347.36M | 0.8% |
DRLL | 2.08% | $267.11M | 0.41% |
FTSD | -2.10% | $212.66M | 0.25% |
XLU | 2.10% | $18.92B | 0.09% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DNLI | 43.54% | $1.98B | -29.08% | 0.00% |
ROIV | 40.55% | $7.81B | 0.00% | 0.00% |
CRNX | 39.98% | $2.82B | -38.08% | 0.00% |
VKTX | 39.92% | $3.11B | -54.96% | 0.00% |
HZO | 37.65% | $461.89M | -20.45% | 0.00% |
NERV | 36.77% | $10.14M | -42.46% | 0.00% |
NTLA | 36.39% | $979.90M | -61.98% | 0.00% |
AGIO | 36.20% | $1.71B | -9.48% | 0.00% |
COGT | 35.65% | $563.59M | -33.91% | 0.00% |
IDYA | 34.63% | $1.64B | -51.42% | 0.00% |
ARWR | 34.55% | $2.13B | -37.62% | 0.00% |
COHR | 33.92% | $12.26B | +33.56% | 0.00% |
CLDX | 33.30% | $1.35B | -43.92% | 0.00% |
VERA | 33.13% | $1.25B | -47.06% | 0.00% |
STOK | 32.84% | $518.67M | -35.42% | 0.00% |
RARE | 32.41% | $3.36B | -11.00% | 0.00% |
RVMD | 32.30% | $7.23B | +1.76% | 0.00% |
XENE | 31.95% | $2.34B | -20.72% | 0.00% |
APGE | 31.33% | $2.40B | -12.34% | 0.00% |
KURA | 31.22% | $540.23M | -70.88% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -17.23% | $360.65M | 1.43% |
TAIL | -16.80% | $118.71M | 0.59% |
VIXY | -16.31% | $126.83M | 0.85% |
TPMN | -11.63% | $30.83M | 0.65% |
UUP | -9.35% | $277.56M | 0.77% |
BILZ | -9.17% | $871.57M | 0.14% |
CTA | -8.63% | $1.08B | 0.76% |
EWW | -6.49% | $1.95B | 0.5% |
UGA | -6.35% | $72.78M | 0.97% |
BNO | -6.31% | $87.37M | 1% |
USO | -6.11% | $883.65M | 0.6% |
DBE | -5.94% | $46.64M | 0.77% |
USDU | -5.91% | $169.80M | 0.5% |
USL | -5.35% | $40.94M | 0.85% |
KCCA | -5.06% | $95.01M | 0.87% |
BIL | -5.06% | $45.04B | 0.1356% |
OILK | -4.80% | $61.94M | 0.69% |
FLMX | -4.75% | $49.19M | 0.19% |
GBIL | -4.30% | $6.06B | 0.12% |
DBO | -3.43% | $180.57M | 0.77% |